Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Refractory Extranodal Nasal NK/T-Cell Lymphoma with CNS Involvement Treated with Radiotherapy and Pralatrexate: Case Report

Rico Enrique, Hematologist

Blood (2015) 126 (23): 5060.

https://doi.org/10.1182/blood.V126.23.5060.5060

Published: 2015

Journal Articles

The Pim Kinase Inhibitor SGI-1776 Chemosensitizes Multidrug Resistant Cells by Both Inhibiting Drug Transport by ABCB1 and ABCG2 and Decreasing ABCB1 and ABCG2 Surface Expression On Cells That Overexpress Pim-1.

Karthika Natarajan, PhD, Jasjeet Bhullar, PhD, Suneet Shukla, PhD, Mehmet Burcu, BS, Suresh V. Ambudkar, PhD, Maria R. Baer, M.D.

Blood (2012) 120 (21): 2462.

https://doi.org/10.1182/blood.V120.21.2462.2462

Published: 2012

Journal Articles

Itraconazol Inhibits the P-Glycoprotein Pump and Increases Vincristine Induced Toxicity in Patients with Acute Lymphoblastic Leukemia Carrying a Genetic Variant of the MDR1 Gene

D. Maroeska W.M. te Loo, MD, PhD, Melanie Hagleitner, Peter M. Hoogerbrugge, MD, PhD, Rosalinde Masareeuw, Marieke Coenen

Blood (2011) 118 (21): 231.

https://doi.org/10.1182/blood.V118.21.231.231

Published: 2011

Journal Articles

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Devendra K Hiwase, Jane Engler, Verity Saunders, Deborah L. White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 1205.

https://doi.org/10.1182/blood.V116.21.1205.1205

Published: 2010

Journal Articles

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

Carine Tang, BSc., (Hons), Lisa Schafranek, BSc., (Hons), Dale Watkins, BSc., (Hons), Wendy T Parker, PhD, Jodi Prime, BSc., Deborah L White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 3383.

https://doi.org/10.1182/blood.V116.21.3383.3383

Published: 2010

Journal Articles

A Polymorphism In the 3'UTR Region of ABCB1 Is Associated with Increased Allele Activity with Corresponding Increases In P-Glycoprotein Expression and Function

Nada Bajuaifer, Martin Grundy, BSc, Robert Hills, MA, MSc, DPhil, Nigel H. Russell, MD, Monica Pallis, PhD, Claire Seedhouse

Blood (2010) 116 (21): 3990.

https://doi.org/10.1182/blood.V116.21.3990.3990

Published: 2010

Journal Articles

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hars, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson, for the Cancer and Leukemia Group B

Blood (2010) 116 (9): 1413–1421.

https://doi.org/10.1182/blood-2009-07-229492

Published: 2010

Journal Articles

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

Eyal C. Attar, MD, Kati Maharry, MAS, Krzysztof Mrózek, MD, PhD, Michael D. Radmacher, PhD, Susan P. Whitman, PhD, Peter Paschka, MD, Christian Langer, MD, Kelsi B. Holland, MS, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard A. Larson, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 1616.

https://doi.org/10.1182/blood.V114.22.1616.1616

Published: 2009

Journal Articles

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

Stephane Bouchet, Stephanie Dulucq, Karine Titier, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon

Blood (2009) 114 (22): 2750.

https://doi.org/10.1182/blood.V114.22.2750.2750

Published: 2009

Journal Articles

The Investigation of Mechanisms Underlying Hoechst 33342 Efflux in Myeloma ‘Side Population' Cells.

Yen Siew Loh, PhD, John D Allen, PhD, Ammira Al-shabeeb, PhD, Ross D. Brown, PhD, MBA, Jia Li, Joshua Douglas, Professor, Daniel Sze, A/Professor

Blood (2009) 114 (22): 2759.

https://doi.org/10.1182/blood.V114.22.2759.2759

Published: 2009

Journal Articles

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Joanne Mountford, PhD, Andrea Davies, Niove E Jordanides, Athina Giannoudis, Claire M Lucas, Sophia Hatziieremia, Robert J Harris, Heather G Jorgensen, Munir Pirmohamed, Tessa L Holyoake, Richard E Clark

Blood (2008) 112 (11): 3205.

https://doi.org/10.1182/blood.V112.11.3205.3205

Published: 2008

Journal Articles

PKC412 Directly Inhibits the Serine/Threonine Protein Kinase Pim-1 in Cell Lines and Acute Myeloid Leukemia Cells as a Novel Mechanism of Inhibition of Multidrug Resistance

Yi ngqiu Xie, Mehmet Burcu, Maria R. Baer

Blood (2008) 112 (11): 2655.

https://doi.org/10.1182/blood.V112.11.2655.2655

Published: 2008

Journal Articles

Lyn Kinase Overexpression Is One of the Mechanisms of Resistance to Nilotinib In Chronic Myeloid Leukemia

Francois-Xavi er Mahon, Sandrine Hayette, Valerie Lagarde, Franck E Nicolini, MD, PhD, Francis Belloc, Cedric Leroy, Serge Roche, Paul Manley, PhD, Coralie Belanger, Gabriel Etienne, Jean-Max Pasquet

Blood (2008) 112 (11): 3181.

https://doi.org/10.1182/blood.V112.11.3181.3181

Published: 2008

Journal Articles

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Jane R Engler, Amity Frede, Andrew C W Zannettino, PhD, Deborah L White, PhD, Timothy P Hughes, MD

Blood (2008) 112 (11): 196.

https://doi.org/10.1182/blood.V112.11.196.196

Published: 2008

Journal Articles

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Andrea Davies, PhD, Athina Giannoudis, PhD, Claire M. Lucas, BSc, Robert J. Harris, PhD, Paul W. Manley, PhD, Munir Pirmohamed, PhD, FRCP, FRCP(E), Richard E. Clark, MA, MD, FRCP, FRCPat

Blood (2007) 110 (11): 2364.

https://doi.org/10.1182/blood.V110.11.2364.2364

Published: 2007

Journal Articles

Reduced Effect of Inotuzumab Ozogamicin (CMC544) on P-Glycoprotein Positive Malignant B Cells and Its Restoration by Multidrug Resistance Modifiers.

Akihiro Takeshita, PhD, MD, Kaori Shinjo, PhD, MD, Nozomi Yamakage, MA, Takaaki Ono, MD, Isao Hirano, MD, Kenji Okinaka, MD, Hirotaka Matsui, PhD, MD, Satoki Nakamura, MD, Kazuyuki Shigeno, MD, Masato Maekawa, PhD, MD, Kazunori Ohnishi, PhD, MD, Ryuzo Ohno, PhD, MD

Blood (2007) 110 (11): 2378.

https://doi.org/10.1182/blood.V110.11.2378.2378

Published: 2007

Journal Articles

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Kieran L. O’Loughlin, BS, Hans Minderman, PhD, Laurie A. Ford, BS, Maria R. Baer, MD

Blood (2007) 110 (11): 2380.

https://doi.org/10.1182/blood.V110.11.2380.2380

Published: 2007

Journal Articles

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

Jonathan E. Kolitz, Vera Hars, Daniel J. DeAngelo, Steven L. Allen, Thomas C. Shea, Ravi Vij, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Stephen L. George, Richard A. Larson

Blood (2007) 110 (11): 157.

https://doi.org/10.1182/blood.V110.11.157.157

Published: 2007

Journal Articles

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Devendra K. Hiwase, MD, Deborah L. White, Verity A. Saunders, Phuong Dang, Amity Venables, Laura Eadie, Steph Zrim, L. Bik To, MD, Junia V. Melo, MD, Timothy P. Hughes, MD

Blood (2007) 110 (11): 1937.

https://doi.org/10.1182/blood.V110.11.1937.1937

Published: 2007

Journal Articles

Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Ben L. Sanford, MS, Sandra M. Bothun, BS, Krzysztof Mrozek, PhD, Kieran L. O’Loughlin, BS, Jonathan E. Kolitz, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Bayard L. Powell, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 296.

https://doi.org/10.1182/blood.V110.11.296.296

Published: 2007

NARROW

Refractory Extranodal Nasal NK/T-Cell Lymphoma with CNS Involvement Treated with Radiotherapy and Pralatrexate: Case Report

The Pim Kinase Inhibitor SGI-1776 Chemosensitizes Multidrug Resistant Cells by Both Inhibiting Drug Transport by ABCB1 and ABCG2 and Decreasing ABCB1 and ABCG2 Surface Expression On Cells That Overexpress Pim-1.

Itraconazol Inhibits the P-Glycoprotein Pump and Increases Vincristine Induced Toxicity in Patients with Acute Lymphoblastic Leukemia Carrying a Genetic Variant of the MDR1 Gene

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

A Polymorphism In the 3'UTR Region of ABCB1 Is Associated with Increased Allele Activity with Corresponding Increases In P-Glycoprotein Expression and Function

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

The Investigation of Mechanisms Underlying Hoechst 33342 Efflux in Myeloma ‘Side Population' Cells.

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

PKC412 Directly Inhibits the Serine/Threonine Protein Kinase Pim-1 in Cell Lines and Acute Myeloid Leukemia Cells as a Novel Mechanism of Inhibition of Multidrug Resistance

Lyn Kinase Overexpression Is One of the Mechanisms of Resistance to Nilotinib In Chronic Myeloid Leukemia

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Reduced Effect of Inotuzumab Ozogamicin (CMC544) on P-Glycoprotein Positive Malignant B Cells and Its Restoration by Multidrug Resistance Modifiers.

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only